Mega-funds can justify paying "stupid prices" at the seed stage because they aren't underwriting a seed-stage return. Instead, they are buying an option on the next, much larger round where they'll deploy real capital. This allows them to outbid smaller funds who need to generate returns from the initial investment itself.

Large, multi-stage funds can pay any price for seed rounds because the check size is immaterial to their fund's success. They view seed investments not on their own return potential, but as an option to secure pro-rata rights in future, massive growth rounds.

David Craver asserts that being an active private market investor is an "imperative" for success in public markets. The research and insights gained from late-stage, pre-IPO companies provide crucial information that directly informs and strengthens a firm's public equity investment strategy in an interconnected landscape.

VCs are actively deploying capital in anticipation of the IPO window reopening in 2026. Driven by pressure from their own LPs to return capital, they cannot afford to be on the sidelines and are ensuring their portfolio companies are funded and ready to go public.

Public market investors often have only 90 days to diligence an IPO using the S-1 filing. Crossover investors who engage with companies privately for years develop a deep, historical understanding of the business and management. This long-term context provides a significant informational advantage and allows for higher conviction.

The roles are blurring: firms like A16Z don't just exit at IPO. They may become the largest buyer *in* the IPO, as they did with Samsara, if they believe the public market is undervaluing the company's long-term prospects.

For late-stage startups, securing a pre-IPO round led by a premier public market investor like Fidelity is a strategic move. It provides more than capital; it offers a crucial stamp of approval that builds significant confidence and credibility with Wall Street ahead of an IPO.

Large LPs are increasingly investing directly in top-tier private tech companies, circumventing traditional VC funds. They gain access through SPVs with minimal fees, creating a competitive dynamic where VCs must justify their value proposition against direct, low-cost access to the most sought-after deals.

A successful biotech IPO isn't about attracting the public; it's about securing commitments from crossover investors beforehand. These investors must "bring their own beer to the party" by participating in the IPO. Their presence validates the company, stabilizes the offering, and is essential for attracting generalist funds later.